Video-Tumorboard PLUS

NCT ID: NCT06980740

Last Updated: 2025-05-20

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 300 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-05-01
• Study Completion Date: 2027-05-31

Brief Summary

In weekly expert meetings for oncological diagnostics and therapy, known as tumor boards, individual therapy recommendations are developed for cancer patients. By further developing and optimizing the CCCs' video tumor boards, initially using skin cancer as an example, we want to ensure that more patients can benefit from the expertise of several specialist disciplines and innovations - regardless of where they live.

Conditions

Malignant Melanoma; Telemedicine

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: OTHER

Study Groups

1

Retrospective

No interventions assigned to this group

2

Prospective

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• The study includes adult, external patients who, according to the certification requirements of the German Cancer Society, should be presented to the CCCs in a tumor board .

• Minimum age 18 years
• Consent to participate in the study (signing of patient consent) should be presented in vTB+ according to the doctor, based on the disease/diagnosis, especially in the case of:

• Malignant melanoma from stage IIB
• Malignant melanoma and stage shift/recurrence o Extracutaneous melanoma o Cutaneous lymphoma from stage Ib o Problem cases with malignant, epithelial tumors (BCC, SCC) with interdisciplinary issues, e.g. complicated localization, extension/ infiltration (e.g. Ulcus rodens, Ulcus terebrans), metastasized tumors, immunosuppressed patients o all rare malignant skin tumors (including Merkel cell carcinoma, DFSP, MFH, leiomyosarcoma, S., Kaposi's sarcoma, angiosarcoma), regardless of stage o severe side effects from drug-based tumor therapy • is an external patient: An external patient is someone who receives tumor therapy exclusively or in co-treatment in the branch or in an external clinic (in distinction to patients without prior treatment for initial presentation at the CCC) . This also applies to patients who are only seen once at the vTB.

In this case, revenue/cost aspects and the DKG requirement are ignored. This means that so-called external patients can also be treated at the center, including initiation of therapy. The decisive factor is the presentation of the external patient (personal presentation of the external patients is not mandatory) and that external co-treaters are consistently informed and involved.

• has a medical license
• has dermatological patients who are eligible to be presented in the vTB+

Exclusion Criteria

Patients will be excluded from the study if they meet the following criteria:

• Linguistic or other limitations (such as dementia) that prevent independent consent to the privacy policy.
• No consent to participate in the study (patient consent) or withdrawal of consent during the course of the study In addition, external physicians will be excluded from the study if no joint cooperation agreement can be negotiated and signed.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Deutsche Krebshilfe e.V., Bonn (Germany)

OTHER

Sponsor Role: collaborator

University Hospital, Bonn

OTHER

Sponsor Role: collaborator

University Hospital Dresden

OTHER

Sponsor Role: collaborator

University Hospital Muenster

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Philipp Lenz, MD

Role: PRINCIPAL_INVESTIGATOR

Westdeutsches Tumorzentrum Münster, Universitätsklinikum Münster

Locations

Abteilung für Integrierte Onkologie - CIO Bonn, Universitätsklinikum Bonn

Bonn, , Germany

Site Status: NOT_YET_RECRUITING

Nationales Centrum für Tumorerkrankungen Klinik u. Poliklinik für Dermatologie, Universitätsklinikum Dresden

Dresden, , Germany

Site Status: RECRUITING

Westdeutsches Tumorzentrum Münster, Universitätsklinikum Münster

Münster, , Germany

Site Status: NOT_YET_RECRUITING

Countries

Germany

Central Contacts

Philipp Lenz, MD

Role: CONTACT

philipp.lenz@ukmuenster.de

+49 251 83 43745

Friedegund Meier, MD

Role: CONTACT

friedegund.meier@ukdd.de

+49 351 4583677

Facility Contacts

Ingo Schmidt-Wolf, MD

Role: primary

ingo.schmidt-wolf@ukbonn.de

+49 228 28717033

Friedegund Meier, MD

Role: primary

friedegund.meier@ukdd.de

+49 351 4583677

Philipp Lenz, MD

Role: primary

philipp.lenz@ukmuenster.de

+49 251 83 43745

Other Identifiers

2025-275-b-S

Identifier Type: OTHER

Identifier Source: secondary_id

BO ff (Multi)-EK-16012025

Identifier Type: -

Identifier Source: org_study_id